New hope for chronic dry eye from Graft-Versus-Host disease: expanded access to d-MAPPS eye drops
NCT ID NCT07210619
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This expanded access program makes an investigational eye drop called d-MAPPS available to adults with chronic ocular graft-versus-host disease (oGVHD), a painful dry eye condition that can occur after a stem cell or bone marrow transplant. The treatment is a protein-based solution derived from donor cells. Participants must have moderate to severe symptoms and be in stable overall health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- d-MAPPS ophthalmic solution (a protein-based eye drop derived from donor cells)
- What this could lead to
- If successful, this expanded access program could provide a new treatment option for people with chronic dry eye caused by graft-versus-host disease.
- What could go wrong
- This is an expanded access program, not a full clinical trial, so data on effectiveness and safety is still limited. The treatment may not work for everyone and could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OCULAR GRAFT-VERSUS-HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.